
QURE
uniQure N.V.
$18.64
Open: $18.99 High: $19.08 Low: $18.53 Close: $18.79
Range: 2022-06-27 - 2022-06-28
Volume:202,201Market: Open
Powered by Finage Stock APIDelayed data
QURE
uniQure N.V. PAASHEUVELWEG 25A https://www.uniqure.com
uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.- CEO: Matthew C. Kapusta
- Employees: 463
- Sector: Healthcare
- Industry: Biotechnology
QURE News
Latest news about the QURE
- Biogen's experimental eye treatment fails to meet study goal by Reuters at 5/14/21, 3:25 PMView More →
- 7 Triple-A Stocks to Buy -- With 100% Street Support by Investor Place at 5/22/18, 12:00 AMView More →